

FORM PTO-1390 (Modified)  
(REV 10-95)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

195707US0PCT

U.S. APPLICATION NO. (IF KNOWN; SEE 37 CFR

09/622583


INTERNATIONAL APPLICATION NO.  
PCT/FR99/00386INTERNATIONAL FILING DATE  
19 FEBRUARY 1999PRIORITY DATE CLAIMED  
20 FEBRUARY 1998 (EARLIEST)

TITLE OF INVENTION

METHOD FOR SELECTING TUMOURS EXPRESSING HLA-G WHICH ARE SENSITIVE TO ANTICANCER  
TREATMENT, AND USES THEREOF

APPLICANT(S) FOR DO/EO/US

Edgardo D. CAROSELLA, et al.



Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

## Items 13 to 18 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.  
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☐ Certificate of Mailing by Express Mail
19. ☒ Other items or information:

Request for Consideration of Documents Cited in International Search Report

Notice of Priority

PCT/IB/304

PCT/IB/308

Drawings ( 12 Sheets )

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR <b>09/622583</b> )	INTERNATIONAL APPLICATION NO. <b>PCT/FR99/00386</b>	ATTORNEY'S DOCKET NUMBER <b>195707US0PCT</b>
--	--	---

20. The following fees are submitted:

**BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :**

- |  |                 |
|--|-----------------|
| <input checked="" type="checkbox"/> Search Report has been prepared by the EPO or JPO .....  | <b>\$840.00</b> |
| <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) .....  | <b>\$670.00</b> |
| <input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ..... | <b>\$760.00</b> |
| <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....          | <b>\$970.00</b> |
| <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....       | <b>\$96.00</b>  |

**ENTER APPROPRIATE BASIC FEE AMOUNT =****\$840.00**
 Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☒ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).
**\$130.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	13 - 20 =	0	x \$18.00
Independent claims	10 - 3 =	7	x \$78.00

**\$0.00****\$546.00**Multiple Dependent Claims (check if applicable). ☐**\$0.00****TOTAL OF ABOVE CALCULATIONS =****\$1,516.00**Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). ☐**\$0.00****SUBTOTAL =****\$1,516.00**Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +**\$0.00****TOTAL NATIONAL FEE =****\$1,516.00**Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐**\$0.00****TOTAL FEES ENCLOSED =****\$1,516.00**

Amount to be: refunded	\$
charged	\$

☒ A check in the amount of **\$1,516.00** to cover the above fees is enclosed.
☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees.  
 A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **15-0030** A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

NEUSTADT, P.C.

**22850**
**Surinder Sachar**  
 Registration No. 34,423

SIGNATURE

Norman F. Oblon

NAME

**24,618**

REGISTRATION NUMBER

DATE

Aug. 21, 2000

09/622583

534 Rec'd PCT/PTO 21 AUG 2000

Docket No. 195707US-369-846-0 PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF: :  
EDGARDO D. CAROSELLA ET AL : ATTN: APPLICATION DIVISION  
SERIAL NO: NEW APPLICATION :  
(Based on PCT/FR99/00386)  
FILED: HEREWITH :  
FOR: METHOD FOR SELECTING :  
TUMOURS EXPRESSING HLA-G  
WHICH ARE SENSITIVE TO  
ANTICANCER TREATMENT,  
AND USES THEREOF

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows.

IN THE CLAIMS

Please amend the claims as follows.

10. (Amended) An antitumor composition which can be used for solid tumours expressing at least one HLA-G isoform, characterized in that it consists essentially of at least one factor for regulating the transcription and/or the expression of HLA-Gs [Composition according to Claim 9] , characterized in that said regulation factor is selected from the group consisting of the regulation factors obtained using the method according to Claim 4, factors

which are antagonists of HLA-G activation agents, antisense nucleic acids and hormonal inhibitors of the transcription and/or of the expression of said HLA-Gs.--

REMARKS

Claims 1-13 are active in this application.

Claim 10 has been amended to incorporate the recitations of Claim 9 and thereby depend from Claim 4 only. No new matter is believed to have been added to this application by these amendments.

Applicants submit that the present application is ready for examination on the merits.

Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Attorney of Record  
Registration No. 24,618

James J. Kelly, Ph.D.  
Registration No. 41,504

Surinder Sachar  
Registration No. 34,423



**22850**

(703) 413-3000  
Fax #: (703) 413-2220  
JK/NFO/rac

I:\atty\JK\195707us-PR.wpd

WO 99/42128

PCT/FR99/00386  
534 Rec'd PCT/PTO 21 AUG 2000

**METHOD FOR SELECTING TUMOURS EXPRESSING HLA-G WHICH ARE  
SENSITIVE TO ANTICANCER TREATMENT, AND USES THEREOF.**

The present invention relates to a method for  
5 selecting solid tumours which are sensitive to  
anticancer treatment, which inhibits or prevents the  
HLA-G activity of said solid tumours, and to uses  
thereof.

Major histocompatibility complex (MHC) antigens  
10 are divided up into several classes, class I antigens  
(HLA-A, HLA-B and HLA-C) which exhibit 3 globular  
domains ( $\alpha 1$ ,  $\alpha 2$  and  $\alpha 3$ ) and whose  $\alpha 3$  domain is  
associated with  $\beta 2$  microglobulin, class II antigens  
(HLA-DP, HLA-DQ and HLA-DR) and class III antigens  
15 (complement).

Class I antigens comprise, besides the  
abovementioned antigens, other antigens, so-called  
unconventional class I antigens, and in particular the  
HLA-E, HLA-F and HLA-G antigens; the latter, in  
20 particular, is expressed by extravillous trophoblasts  
of normal human placenta and thymic epithelial cells.

The sequence of the HLA-G gene (HLA-6.0 gene)  
was described by Geraghty et al. (Proc. Natl. Acad.  
Sci. USA, 1987, 84, 9145-9149): it comprises 4396 base  
25 pairs and exhibits an intron/exon organization which is  
homologous to that of the HLA-A, -B and -C genes. More  
specifically, this gene comprises 8 exons, 7 introns  
and a 3' untranslated end; the 8 exons correspond  
respectively to: exon 1: signal sequence, exon 2:  $\alpha 1$   
30 extracellular domain, exon 3:  $\alpha 2$  extracellular domain,  
exon 4:  $\alpha 3$  extracellular domain, exon 5: transmembrane  
region, exon 6: cytoplasmic domain I, exon 7:  
cytoplasmic domain II (untranslated), exon 8:  
cytoplasmic domain III (untranslated) and 3'  
35 untranslated region (Geraghty et al., mentioned above:  
Ellis et al., J. Immunol., 1990, 144, 731-735;  
Kirszenbaum M. et al., *Oncogeny of hematopoiesis.*  
*Aplastic anemia* Eds. E. Gluckman, L. Coulombel,

Colloque INSERM/John Libbey Eurotext Ltd). However, the HLA-G gene differs from the other class I genes in that the in-frame translation stop codon is located in the second codon of exon 6; consequently, the cytoplasmic region of the protein encoded by this HLA-6.0 gene is considerably shorter than the cytoplasmic regions of the HLA-A, -B and -C proteins.

These HLA-G antigens are essentially expressed by the cytotrophoblastic cells of the placenta and are considered to play a role in protecting the foetus (absence of rejection by the mother). In addition, since the HLA-G antigen is monomorphic, it may also be involved in placental cell growth or function (Kovats et al., Science, 1990 248, 220-223).

Other research relating to this unconventional class I antigen (Ishitani et al., Proc. Natl. Acad. Sci. USA, 1992, 89, 3947-3951) has shown that the primary transcript of the HLA-G gene can be spliced in several ways, and produces at least 3 distinct mature mRNAs: the primary transcript of HLA-G provides a 1200-bp complete copy (G1), a 900-bp fragment (G2) and a 600-bp fragment (G3).

The G1 transcript does not comprise exon 7, and corresponds to the sequence described by Ellis et al. (mentioned above), i.e. it encodes a protein which comprises a leader sequence, three external domains, a transmembrane region and a cytoplasmic sequence. The G2 mRNA does not comprise exon 3, i.e. it encodes a protein in which the  $\alpha 1$  and  $\alpha 3$  domains are directly joined; the G3 mRNA contains neither exon 3 nor exon 4, i.e. it encodes a protein in which the  $\alpha 1$  domain and the transmembrane sequence are directly joined.

The splicing which prevails so as to obtain the HLA-G2 antigen leads to the joining of an adenine (A) (originating from the domain encoding  $\alpha 1$ ) with an AC sequence (derived from the domain encoding  $\alpha 3$ ), which leads to the creation of an AAC (asparagine) codon in place of the GAC (aspartic acid) codon encountered at

the start of the sequence encoding the  $\alpha 3$  domain in HLA-G1.

The splicing generated so as to obtain HLA-G3 does not lead to the formation of a new codon in the  
5 splicing zone.

The authors of this article also analysed the various proteins expressed: the 3 mRNAs are translated into protein in the 221-G cell line.

Some of the inventors have shown the existence  
10 of other spliced forms of HLA-G mRNA: the HLA-G4 transcript which does not include exon 4; the HLA-G5 transcript which includes intron 4 between exons 4 and 5, thus causing a modification of the reading frame during the translation of this transcript and in  
15 particular the appearance of a stop codon after amino acid 21 of intron 4; and the HLA-G6 transcript which possesses intron 4, but has lost exon 3 (Kirszenbaum M. et al., *Proc. Natl. Acad. Sci. USA*, 1994, 91, 4209-4213; European Application EP 0 677 582; Kirszenbaum M.  
20 et al., *Human Immunol.*, 1995, 43, 237-241; Moreau P. et al., *Human Immunol.*, 1995, 43, 231-236); they have also shown that these various transcripts are expressed in several types of foetal and adult human cells, in particular in lymphocytes (Kirszenbaum M. et al., *Human*  
25 *Immunol.*, 1995, mentioned above; Moreau P. et al., *Human Immunol.* 1995, mentioned above).

Some of the inventors have also shown that NK cells express no HLA-G transcript (Teyssier M. et al., *Nat. Immunol.*, 1995, 14, 262-270; Moreau P. et al.,  
30 *Human Immunol.*, 1997, 52, 41-46).

At least 6 different HLA-G mRNAs thus exist which potentially encode 6 protein isoforms of HLA-G, of which 4 are membrane-bound (HLA-G1, G2, G3 and G4) and 2 are soluble (G5 and G6).

35 Although the foetus can be considered to be a semi-allograft, the foetal cells survive and are not rejected by the mother; it has become apparent that the HLA-G molecules expressed at the surface of the trophoblasts protect the foetal cells against lysis by

maternal natural killer (NK) cells from the uterine decidua and from peripheral blood (Carosella E.D. et al., C.R. Acad. Sci., 318, 827-830; Carosella E.D. et al., *Immunol. Today*, 1996, 407-409; Rouas-Freiss N. et al., *PNAS*, 1997, 94, 5249-5254).

Previous studies have shown that the expression of HLA-G molecules at the surface of transfected target cells makes it possible to protect said target cells against the cytolytic activity of NK cells from the decidual layer of the maternal endometrium (Chumbley G. et al., *Cell Immunol.*, 1994, 155, 312-322; Deniz G. et al., *J. Immunol.*, 1994, 152, 4255-4261; Rouas-Freiss N. et al., *Proc. Natl. Acad. Sci.*, 1997, 94, 5249-5254). It should be noted that these target cells are obtained by transfection with vectors comprising either HLA-G genomic DNA which potentially generates all the alternative transcripts, or with vectors containing the HLA-G1 and HLA-G2 cDNAs encoding the HLA-G1 and HLA-G2 protein isoforms (European Patent Application No. 0 677 582 and Application PCT/FR98/00333).

NK cells express receptors for class I MHC molecules (killer inhibitory receptors or KIR, or NKIR for NK inhibitory receptors) which are responsible for the inhibition of cytotoxicity when these HLA molecules, acting as ligands, are recognized by these receptors; for example, N. Rouas-Freiss et al., (*Proc. Natl. Acad. Sci.*, 1997, 94, 5249-5254) showed that the expression of HLA-G protected K562 (human erythroleukaemia cell line) target cells transfected with the HLA-G1 and G2 isoforms against lysis. These cells are usually sensitive to NK cells.

These results testify to the fundamental role of the HLA-G molecule as an immunotolerance antigen. These results have been broadened to all of the membrane-bound isoforms. The cDNAs encoding the HLA-G1, G2, G3 and G4 isoforms which are expressed, after transfection, in various cell types, in particular transfected K562 cells and M8 tumour cells, inhibit NK and CTL cytotoxic functions.



Given the important role that the HLA-G molecule may play, the inventors, continuing with their work, more particularly studied tumour cells, and gave themselves in particular the aim of providing tools for  
5 selecting solid tumours which are sensitive to a treatment which inhibits the HLA-G antigens present in particular on certain tumours.

The subject of the present invention is a method for establishing the HLA-G transcription profile  
10 of a solid tumour with a view to selecting a treatment which is suited to said tumour and/or with a view to monitoring the evolution of said tumour, characterized in that it comprises:

- (i) the removal of a tumour sample;
- 15 (ii) the extraction of the mRNA from said sample; a modified Chomczynski and Sacchi method using the RNA reagent NOW (Ozyme, France) can in particular be used;
- (iii) the reverse transcription (RT) of said  
20 RNA;
- (iv) the successive or simultaneous amplifications of the cDNAs obtained in (iii), in the presence of primers specific for each HLA-G isoform, and the analysis of the amplification products obtained  
25 by electrophoresis and/or specific hybridization and
- (v) the establishment of the HLA-G transcription profile of said sample.

Preferably, the reverse transcriptions are primed with oligo-dTs on mRNA which is denatured in  
30 advance, for example at 65°C, in the presence of a reverse transcriptase such as M-MLV reverse transcriptase (Gibco-BRL, Life technologies).

Also preferably, the cDNA amplification is carried out by polymerase chain reaction (PCR) using  
35 primers specific for the various HLA-G isoforms, in accordance with the following tables:

Primers	Nucleotide sequences	Hybridization temperatures (°C)	Isoforms amplified
G.257 G3.U	5'-GGAAGAGGAGACACGGAACA 5'-GGCTGGTCTCTGCACAAAGAGA	61	G1, G2, G3 G4, G5, G6
G.526 G3.U	5'-CCAATGTGGCTGAACAAAGG 5'-GGCTGGTCTCTGCACAAAGAGA	61	G1, G4, G5
G.-3-4 G3.U	5'-ACCAGAGCGAGGCCAAGCAG 5'-GGCTGGTCTCTGCACAAAGAGA	65	G3
G.-3 G3.U	5'-ACCAGAGCGAGGCCAACCCC 5'-GGCTGGTCTCTGCACAAAGAGA	65	G2, G6
G.-3 G.i4b	5'-ACCAGAGCGAGGCCAACCCC 5'-AAAGGAGGTGAAGGTGAGGG	61	G6
G.526 G.i4b	5'-CCAATGTGGCTGAACAAAGG 5'-AAAGGAGGTGAAGGTGAGGG	61	G5

Probes	Nucleotide sequences	Hybridization temperatures (°C)	Isoforms detected
GR	5'-GGTCTGCAGGTTCACTCTGTC	60	HLA-G1, G2, G3, G4, G5, G6
G.647 F	5'-CCACCACCCTGTCTTTGACT	60	HLA-G1, G2, G5, G6
G.I4 F	GAGGCATCATGTCTGTTAGG	55	HLA-G5, G6
G.927 F	5'-ATCATGGGTATCGTTGCTGG	55	HLA-G1, G2, G3, G4, G5 and G6

The inventors found, surprisingly, that at least some solid tumours express the HLA-G antigen, and

showed that this HLA-G antigen plays a functional role in protecting tumour cells (solid tumours) against destruction by NK cells. They also showed the effective presence of certain HLA-G isoforms at the surface of  
5 said tumour cells.

However, also surprisingly, depending on the tumour lines, the HLA-G profile (transcripts and proteins) is different.

For example, in some melanoma lines, the  
10 presence of the HLA-G2/G4 and G3 isoforms can be observed, which protect these lines against NK-cell-induced cell lysis, as does the HLA-G1 isoform in other lines.

In other lines, all of the HLA-G transcripts  
15 are detected. The HLA-G1 protein form is detected by immunofluorescence with an anti-HLA-G antibody, and inhibits NK lysis.

The analysis of biopsies from patients with melanomas reveals a high level of HLA-G transcripts in  
20 some tumours (primary and metastases), associated with a high expression of the HLA-G1 protein which is detectable by immunohistochemistry on frozen sections using an anti-HLA-G1 antibody.

This high HLA-G transcription and expression is  
25 specific for tumour tissue and is not detected in healthy tissue.

In certain melanomas, a dissociation of the transcription of the soluble (G5) and membrane-bound isoforms is observed. The analysis of patients reveals  
30 4 HLA-G transcription and expression profiles.

Transcription profiles	Membrane-bound forms HLA-G1, G2, G3, G4	Soluble forms
Profile 1	-	-
2	++	-
3	-	++
4	++	++

The expression of the soluble protein is detected by immunohistochemistry on patients exhibiting profile P4.

A subject of the present invention is also a method for establishing the HLA-G expression profile of a solid tumour with a view to selecting a treatment which is suited to said tumour and/or with a view to monitoring the evolution of said tumour, characterized in that it comprises:

- (i) the removal of a tumour sample,
- (ii) the preparation of a histological section from said sample,
- (iii) the labelling of the cells of the sample obtained in (ii) with antibodies specific for HLA-G membrane-bound and soluble isoforms, and
- (iv) the establishment of the HLA-G expression profile of said sample by detecting the labelled cells.

A subject of the present invention is also a method for establishing the HLA-G expression profile of a solid tumour with a view to selecting a treatment which is suited to said tumour and/or with a view to monitoring the evolution of said tumour, characterized in that it comprises:

- (i) the removal of a tumour sample,
- (ii) optionally, the labelling of the cells of said sample,
- (iii) the lysis of the cells,
- (iv) the bringing of the lysed cells into contact with various antibodies directed against the class I HLA antigens so as to possibly form HLA-G isoform/antibody complexes, and
- (v) the establishment of the HLA-G expression profile of said sample by detecting the complexes formed in step (iv).

Preferably, in step (iv), immunoprecipitates are obtained which are separated in step (v) by electrophoresis, transferred onto membrane and detected.

In accordance with the invention, said antibodies are preferably monoclonal antibodies.

The investigation of an HLA-G expression by certain tumour cells and/or cells infiltrating the tumour (macrophages, dendritic cells) makes it possible to better evaluate the potentially effective type of treatment.

Specifically, knowledge of the HLA-G expression transcription profile of a solid tumour is vital for choosing the best possible treatment and for following the evolution of the tumour as a function of said treatment.

A subject of the present invention is also a method for selecting factors for regulating the transcription and/or the expression of HLA-Gs by tumour cells (inhibition), this method being characterized in that it comprises:

- (i) the removal of a tumour sample,
- (ii) the isolation of the tumour cells from said sample,
- (iii) the primary culture of the tumour cells obtained in (ii),
- (iv) the addition of the substance to be tested,
- (v) the visualization of the effect obtained by establishing the HLA-G transcription and/or expression profile of said tumour cells after treatment with said substance to be tested, and
- (vi) the testing *in vitro* of the effect of the treatment on the antitumour response (NK and CTL responses).

Advantageously, the cell lines derived from the biopsies make it possible to evaluate the sensitivity to a treatment *in vitro*, and to determine the agents which are capable of reducing the HLA-G expression (the screening tool) with the aim of re-establishing a better antitumour response, in the case of HLA-G-positive tumour cells.

Such cells are advantageously used as a model for studying the transcription and/or the expression of HLA-Gs.

5 A subject of the present invention is also a method for monitoring the evolution of a tumour expressing HLA-G, characterized in that it comprises assaying the soluble form of HLA-G in the sera of patients, as a prognostic factor for tumour dissemination or for the capacity of the tumour to form  
10 metastases.

Said assaying is preferably carried out by a conventional immunological method, using anti-soluble HLA-G antibodies.

15 A subject of the present invention is also an antitumour vaccine which can be used for solid tumours expressing at least one HLA-G isoform, characterized in that it is selected from the group consisting of autologous tumour cells and a soluble HLA-G5 antigen or a fragment thereof; such vaccines induce the formation  
20 of tumour-specific cytotoxic T lymphocytes and of anti-HLA-G antibodies.

When said vaccine consists of autologous cells (in particular tumour cells from the individual to be treated which express at least one HLA-G isoform), said  
25 cells are preferably modified so as to effectively induce the production of anti-HLA-G antibodies. The cells are, for example, subjected to a cholesterol treatment or to a hyperbaric treatment.

Advantageously, said soluble HLA-G antigen, or  
30 a fragment thereof, is coupled to a suitable protein and optionally combined with an adjuvant such as aluminium hydroxide or calcium phosphate.

Said vaccine is preferably administered subcutaneously or intradermally.

35 A subject of the present invention is also an antitumour composition which can be used for solid tumours expressing at least one HLA-G isoform, characterized in that it consists essentially of anti-HLA-G antibodies (passive immunotherapy).

A subject of the present invention is also an antitumour composition which can be used for solid tumours expressing at least one HLA-G isoform, characterized in that it consists essentially of at least one factor for regulating the transcription and/or the expression of HLA-Gs.

According to one advantageous embodiment of said composition, said regulation factor is selected from the group consisting of the regulation factors obtained using the method as defined above, factors which are antagonists of HLA-G activation agents, which have been identified by the inventors [interleukin-10, glucocorticoid, interferons, stress action (radiation, heat shock, heavy metals, oxidative stress)], antisense nucleic acids and hormonal inhibitors of the transcription and/or of the expression of said HLA-Gs.

A subject of the present invention is also products containing anti-HLA-G antibodies and factors for regulating the expression of HLA-Gs as combination products for simultaneous or separate use, or use which is spread out over time, in the treatment of solid tumours expressing at least one HLA-G isoform.

Said regulation factors are as those defined above.

Besides the preceding arrangements, the invention also comprises other arrangements which will emerge from the description which follows, which refers to examples of implementation of the present invention, as well as to the attached drawings in which:

- Figure 1 illustrates:

(A): the RT-PCR analysis of the HLA-G isoform mRNAs in melanoma cells. pan-HLA-G primers [primer G.257 (exon 2) and 3G.U (untranslated 3' end)] are used for the PCR amplification of the HLA-G transcripts corresponding to the various known HLA-G isoforms. The cDNA from JEG-3 choriocarcinoma cells and first trimester trophoblasts (TRO), and peripheral blood mononucleated cells (PBMC) were used, these cells being used as control cells for high transcription levels and

basal transcription levels of HLA-G, respectively. IgR, M8, DRAN and M74 correspond to the amplification of the cDNA of melanoma cell lines. The specific HLA-G bands are revealed by hybridization with the GR-specific probe, which is located on exon 2. The bands corresponding to the transcripts HLA-G1, G2, G3, G4 and G5 are indicated with arrows. The PCR products which were coamplified during the same reaction using  $\beta$ -actin primers are detected on the same membrane with the aid of a  $\beta$ -actin probe;

(B): this figure corresponds to the RT-PCR detection of alternative transcripts in melanoma cells. Primer 3 is specific for the HLA-G2 and soluble HLA-G2 (G6) isoforms which do not possess exon 3. Primer 3.4 makes it possible to distinguish the HLA-G3 mRNA transcripts. Primers G.526 and I4b amplify specifically the HLA-G5 transcript, which corresponds to the soluble form. The PCR products which were coamplified during the same reaction using  $\beta$ -actin primers are detected on the same membrane with the aid of a  $\beta$ -actin probe;

(C): this figure corresponds to the RT-PCR analysis of the HLA-G mRNA in melanoma cells. pan-HLA-G primers [primer G.257 (exon 2) and 3G.U (untranslated 3' end)] are used for the PCR amplification of the HLA-G transcripts corresponding to the various known HLA-G isoforms. The cDNA from JEG-3 choriocarcinoma cells was used, these cells being used as control cells for high transcription levels. IgR, M8 and DRAN correspond to the amplification of the cDNA melanoma cell lines. The specific HLA-G bands are revealed by hybridization with the GR-specific probe, which is located on exon 2. The bands corresponding to the transcripts HLA-G1, G2, G3, G4 and G5 are indicated with arrows. The PCR products which were coamplified during the same reaction using  $\beta$ -actin primers are detected on the same membrane with the aid of a  $\beta$ -actin probe.

- Figure 2 illustrates the RT-PCR analysis of the HLA-G isoform mRNAs in the biopsies of melanoma



metastases (in vivo and ex vivo analysis of skin). The pan-HLA-G primers G.257 and 3G.U are used for the RT-PCR amplification of the HLA-G transcripts from skin metastases ex vivo (MEL) and from biopsies of healthy skin from the same patient (HS); JEG-3 cells and first trimester trophoblasts are used as controls (high level of HLA-G transcription). The HLA-G specific bands are revealed by hybridization with a GR-specific probe which is located in exon 2. The bands corresponding to the transcripts HLA-G1, G2, G3, G4 and G5 are indicated with arrows.

- Figure 3 illustrates the detection of the HLA-G1 proteins in JEG-3 cells but not in IGR and M8 melanoma cells, with the aid of the monoclonal antibody W6/32: the biotinylated surface proteins of melanoma and JEG-3 cells are immunoprecipitated using the monoclonal antibody W6/32; the immunoprecipitates are separated by SDS-PAGE at 12% and transferred onto cellulose membrane. The class I surface molecules are detected with streptavidin-conjugated peroxidase.

- Figure 4 illustrates the immunoprecipitation of the HLA-G isoforms of IGR melanoma cells with an antibody directed against the heavy chain of free HLA-G and with the monoclonal antibodies 4H84 and HCA2. The cells are labelled for 30 min and immunoprecipitated with the specific antibodies, and the immunoprecipitates are analysed by SDS-PAGE at 10%. The antibody 4H84, which reacts with the HLA-G heavy chain (39-KDa band in JEG-3 cells), exhibits cross-reactions with the HLA-A, -B and/or -C heavy chains (45-KDa band in all the cells tested).

- Figure 5 illustrates:

(A): the effect of HLA-G expression in the IGR melanoma on sensitivity to lysis by the clone YT2C2-PR. K562 cells which are transfected either with the vector alone, or with the HLA-G1 vector containing the cDNA, or the HLA-G2 vector and the M8, M74, IGR and DRAN lines are used as target cells (T). The clone YT2C2-PR is used as an effector cell (E) in an effector

cell/target cell (E/T) ratio of 50/1. The results are expressed as the percentage of lysis recorded in 4 h in a chromium 51-release assay. Spontaneous release never exceeds 10% of the maximum release. This experiment is carried out at least 5 times and, each time, produces the same results;

(B): the inhibition of the lysis induced by the clone YT2C2-PR is due to an "off" signal which is transmitted by the IGR and DRAN cells. The M8 line is used as a target cell (T) and is chromium labelled. Clone YT2CT-PR is used as an effector cell (E) in an E/T ratio of 50:1. IGR and DRAN cells are added as inhibitor cells in an inhibitor cell/target cell ratio of 100, 50 and 25:1. 0 indicates that no IGR cell was added in the assay;

(C): the inhibition of the lysis induced by HLA-G-positive melanoma cells (target cells T). This figure illustrates more particularly the effect of HLA-G expression by IGR and DRAN melanoma cells on sensitivity to lysis by the clone YT2C2-PR. Several cell lines which are B-EBV, HLA-G negative [HOM (A3, B27, Cw1), BM (A29, B61 Cw2), SPO (A3, B7, Cw7), SWE (A2, B44, Cw5)] are lysed by the clone YT2C2-PR. This clone is used as an effector cell (E) in an E/T ratio of 50/1. The results are expressed as the percentage of lysis recorded in 4 h in a chromium 51-release assay. Spontaneous release never exceeds 10% of the maximum release;

(D) and (E): these figures show that the M8 HLA-G-negative tumour cells which are transfected with the cDNAs encoding the molecules G1, G2, G3 and G4 inhibit NK lysis (Figure 5E) and the cytotoxic T responses (Figure 5D). Figure 5D comprises, on the x-axis, the effector cells (E) (restricted HLA-A2 lines specific for an influenza peptide)/target cells (T) (transfected M8 lines) ratios and, on the y-axis, the percentage of specific lysis. The table below corresponds to the values obtained in this figure.

E/T ratio	M8-RSV	G1	G2	G3	G4	Genomic
15/1	55%	8%	39%	12%	17%	30%
7/1	52%	6%	42%	10%	14%	25%
3/1	29%	2%	30%	6%	12%	23%

- Figure 5E comprises, on the x-axis, the effector cells (E) (clone YT2C2-PR)/target cells (T) (transfected M8 lines) ratios and, on the y-axis, the percentage of-specific lysis.

- Figure 6 illustrates the detection of HLA-G transcripts in biopsies of human melanomas. The RT-PCR amplifications are carried out, using the abovementioned primers G.257 and G.3U, on biopsies of healthy skin (HS) and on healthy lymph nodes (HLN), on the one hand, and biopsies of lymph node metastases (LNM1 and LMN2). JEG-3 choriocarcinoma cells are used as control cells for high transcription levels. Specific HLA-G bands are revealed by hybridization with the GR-specific probe which is located on exon 2. The bands corresponding to the transcripts HLA-G1, G2, G3, G4 and G5 are indicated with arrows. The PCR products which were coamplified during the same reaction using the  $\beta$ -actin primers are detected on the same membrane with the aid of a  $\beta$ -actin probe.

- Figure 7 illustrates the RT-PCR analysis of the HLA-G transcripts in the biopsies of primary melanoma tumours and in the derived MPP5 primary cell cultures (ex vivo analysis). The abovementioned pan-HLA-G primers are used for the amplification from biopsies of healthy skin (HS1), from skin primary tumours (SPT1) and from tumours in regression (R1) which are obtained from the same patient, and from derived primary cells obtained from a skin tumour tissue (MPP5). The MPP5 cells and the SPT1 biopsy exhibit similar HLA-G transcription levels. JEG-3 cells are used as controls for high levels of HLA-G transcription. The HLA-G-specific bands are revealed by hybridization with a GR-specific probe which is located in exon 2. The bands corresponding to the transcripts

HLA-G1, G2, G3, G4 and G5 are indicated with arrows. The PCR products which were coamplified during the same reaction using the  $\beta$ -actin primers are detected on the same membrane with the aid of a  $\beta$ -actin-specific probe.

5           - Figure 8 illustrates:

          (A) the specific detection of HLA-G5 transcripts by RT-PCR in biopsies of melanomas. The amplification of the HLA-G5 transcript from healthy lymph nodes (HLN), from a skin primary tumour (SPT1) and from two biopsies of lymph node metastases (LNM1 and LNM2) is carried out with the aid of the primers G.526 and G.i4b. The band corresponding to the HLA-G5 transcript is detected by hybridization with an I4F probe which is located in intron 4; JEG-3 cells are used as controls (high levels of HLA-G5 transcription). The band corresponding to the HLA-G5 transcript is indicated with arrows. The PCR products which were coamplified in the same reaction using the  $\beta$ -actin primers are detected on the same membrane with a  $\beta$ -actin-specific probe;

          (B) the immunohistochemical analysis of the soluble HLA-G expression in the LNM1 biopsy. Frozen and acetone-fixed sections of the LNM1 biopsy are positively stained with the anti-melanoma antibody HMB45 (DAKO) and the anti-soluble HLA-G antibody 16G1, whereas the negative control gives no staining, using the Envision anti-mouse, peroxidase system (DAKO) and AEC as substrate.

          It should be fully understood, however, that these examples are given only by way of illustration of the subject of the invention, of which they in no way constitute a limitation.

**EXAMPLE 1: Analysis of the HLA-G profiles of various tumour lines and study of the inhibition of lysis by NK cells.**

#### **A/ MATERIALS AND METHODS**

##### **1/ Cell lines**

The K562 human erythroleukaemia cell line (ATCC) and the immature T cell leukaemia line (clone

YT2C2-PR) with NK activity are maintained in an RPMI 1640 medium supplemented with heat-inactivated foetal calf serum at 10%, 2mM L-glutamine, 1 µg/ml of gentamicin and fungizone (Sigma, Saint-Quentin, France), and cultured at 37°C in a humidified incubator in an atmosphere which is enriched with 5% CO<sub>2</sub>. The K562 transfectants are selected in a medium containing 1 mg/ml of geneticin (G418 sulphate, Sigma).

The HLA-G-positive human choriocarcinoma cell line, named JEG-3 (ATCC), is cultured in a DMEM medium (Sigma) supplemented with heat-inactivated foetal calf serum at 10%, antibiotics and 2 mM L-glutamine. The cell lines do not contain mycoplasmas.

Besides the abovementioned lines, use is made of:

- IGR (HLA-A2, A3, B58/male), M74 (HLA-A1, A2, B8, B14/female), M8 (HLA-A1, A2, B12 and B40/male) and DRAN (HLA-A2, A3, B7, B35, CW5, CW7) melanoma lines,
- first trimester trophoblastic tissues, which are obtained after abortion; these tissues are cut up into thin slices and immediately used to extract the RNA, and
- peripheral blood mononucleated cells (PBMC), which are obtained from healthy volunteers and isolated on a Ficoll-Hypaque 1077 density gradient.

## 2/ Monoclonal antibodies

The following antibodies are used:

W6/32: anti-β2-m-associated class I HLA α chain IgG2a (Sigma); HCA2: anti-HLA-A and G IgG and anti-HLA-G IgG, 87G, 4H84 and 16G1.

## 3/ RT-PCR

Total RNA is extracted from 10<sup>7</sup> cells using the NOW RNA reagent (Biogentex, Inc.) in accordance with the manufacturer's recommendations. The quantity of the RNA is verified by electrophoresis on denaturing 1.5% agarose gel. The cDNAs are prepared from 10 µg of total RNA treated with DNase I (Boehringer Mannheim) using an oligo-(dT)<sub>12-18</sub> primer and the M-MLV reverse transcriptase (GIBCO-BRL). The HLA-G-specific RT-PCR

amplifications are carried out using the following primers: G.257 (exon 2) and G3.U (3'UT) (Ishitani A. et al., *Proc. Natl. Acad. Sci.*, 1992, **89**, 3947-3951; Kirszenbaum M. et al., *Proc. Natl. Acad. Sci.*, 1994, **91**, 4209-4213 and Moreau P. et al., *C.R. Acad. Sci.*, 1995, **318**, 837-842) so as to detect all the HLA-G mRNA isoforms. An amplification specific for each HLA-G mRNA form is carried out using the following sets of primers:

- 10        - G.526 (exon 3) and G3.U (3'UT) for the isoforms G1, G4 and G5;
- G.526 (exon 3) and G.i4b (intron 4) for the isoform G5;
- G.-3 (partially covering exons 2 and 4) and
- 15        G3.U (3'UT) for the isoforms G2 and G6;
- G.3-4 (partially covering exons 2 and 5) and G3.U (3' UT) for the isoform G3.

The cDNAs of the conventional class I HLAs are amplified as described in King et al. (*J. Immunol.*, 20        1996, **156**, 2068-2076), using a unique 5' primer, HLA-5P2, and 3 3' primers, HLA-3pA, HLA-3pB and HLA-3pC, which amplify the mRNAs HLA-A, HLA-B and HLA-C, respectively.

25        The DRA specific primers are described in King et al., mentioned above.

30        A coamplification of the  $\beta$ -actin cDNA is carried out in each experiment using the Clontech test (16 cycles), so as to evaluate the comparative amounts of RNA in the samples. The PCR products are analysed by electrophoresis on 1% agarose gel and stained with ethidium bromide. The specificity of the PCR products is confirmed by alkaline blotting of the fragments in 0.4 N NaOH on nylon membranes (Hybond N+, Amersham, France).

35        The specific HLA-G probes are as follows:

- GR, specific for exon 2,
- G.647 F (5'-CCACCACCCTGTCTTTGACT: specific for exon 4),

- G.I4 F (GAGGCATCATGTCTGTAGG: specific for intron 4), and

- G.927 F (5'-ATCATGGGTATCGTTGCTGG: specific for exon 5).

5 The other probes are as follows:

- HLA-A-specific probe  
(5'GGAGGACCAGACCCAGGACACG),

- HLA-B-specific probe  
(5'AGCTCCGATGACCACAACCTGC)

10 - HLA-C-specific probe (5'TGTCCTAGCTGCCTAGGAG)  
and

- HLA-DRA-specific probe (TGTGATCATCCAGGCCGAG).

The filters are exposed onto Kodak films (Biomax) with amplifying screens for 4 to 16 hours at  
15 -80°C.

#### **4/ Immunoprecipitation of the surface biotinylated proteins and Western blot.**

The surface proteins are labelled with biotin. After washing in PBS,  $1.5 \times 10^7$  cells are incubated in  
20 1 ml of cold PBS containing 5 ml of NHS-SS-biotin (Pierce, Rockford, IL) for 15 min at 4°C. The residual active groups are inhibited in 50 mM  $\text{NH}_4\text{Cl}$  for 10 min at 4°C. The cells are lysed in 1% Triton X100/PBS. The proteins which are precipitated with the W6/32 antibody  
25 are separated on 12% SDS-PAGE, transferred onto nitrocellulose membrane and placed together with a horseradish peroxidase-streptavidin conjugant. After thorough washing of the membrane, the staining reaction is carried out using the ECL Western blotting detection  
30 reagent (Amersham, France), after which the membrane is exposed to a Kodak film at room temperature.

#### **5/ Cytotoxicity assays**

The cytolytic activity of peripheral blood mononucleated cells, of NK cells and of YT2C2-PR cells  
35 (effector cells or E) towards the HLA-G transfectants (target cells or T) is estimated with the aid of chromium 51 4-hour release assays in which the effector cells are mixed with  $5 \times 10^3$  target cells which are labelled with chromium 51 (100  $\mu\text{Ci}$  of sodium

<sup>51</sup>Cr-chromate Amersham, UK), at various E/T ratios, in microtitration plates which have a U-shaped bottom.

After 4 hours at 37°C in a humidified incubator containing 5% CO<sub>2</sub>, 100 µl of supernatant are removed for liquid phase scintillation counting (Wallac 1450 Microbeta, Pharmacia, France). The percentage of specific lysis is calculated as follows:

percentage of specific lysis = [(cpm in the experimental well - cpm of spontaneous release) / (cpm of maximum release - cpm of spontaneous release)] X 100.

The spontaneous release is determined by incubating the labelled target cells (T) with the medium. The maximum release is determined by solubilizing the target cells in 0.1 M HCl. In all the experiments, the spontaneous release is less than 10% with respect to the maximum release. The results are presented as the means of three samples. In the experiments in which the monoclonal antibodies are used to block HLA-G-NK interaction, the target cells are incubated with the corresponding monoclonal antibody, and then washed and incubated with a goat anti-mouse F(ab')<sub>2</sub> antibody (Jackson ImmunoResearch, USA) in order to avoid antibody-dependent cell cytotoxicity (ADCC) by interaction of the receptors for the immunoglobulin Fc fragment, which are expressed on NK cells, with the primary antibody used. The monoclonal antibody toxicities are also verified in each assay and are always less than 3%.

## II-Results

### **1/ Identification of the various HLA-G transcripts in melanoma cell lines.**

The HLA-G cDNAs of 4 melanoma cell lines (IGR, M8, M74 and DRAN) are amplified with the aid of the previously described primers (A. Ishitani et al., *Proc. Natl. Acad. Sci. USA*, 1992, **89**, 3947-3951; M. Kirszenbaum et al., *Proc. Natl. Acad. Sci. USA*, 1994, **91**, 4209-4213), which are derived from the sequences which are specific for exon 2 and for the



untranslated 3' region (see Materials and Methods)  
(Figure 1).

The JEG-3 choriocarcinoma line and trophoblastic cells, which exhibit high levels of HLA-G transcripts, are used as positive controls and the peripheral blood mononucleated cells (PBMC) of healthy volunteers are used as negative controls (low levels of HLA-G transcripts).

The hybridization of the PCR products made it possible to identify significant levels of HLA-G mRNA in 2 melanoma cell lines, namely IGR and M74, whereas no signal can be detected in the M8 melanoma cell line.

In the JEG-3 cells and trophoblasts, all the HLA-G transcripts are detected (Figures 1A and 1C).

In the IGR and DRAN melanoma cells, all the transcripts are also detected by the pan-HLA-G primers (Figures 1A and 1C).

However, the pan-HLA-G primers do not make it possible to distinguish between the HLA-G1 and HLA-G5 signals, which are both present, in a band corresponding to 1000 bp, nor between the HLA-G2 and HLA-G1 signals, which comigrate in the form of a 600-bp fragment. RT-PCR identification makes it possible to isolate the isoforms with the aid of specific primers (P. Moreau et al., C.R. Acad. Sci., 1995, **318**, 837-842) (see Materials and Methods).

The IGR and DRAN cells express all the HLA-G isoforms in the form of transcripts, HLA-G4 and HLA-G5 being expressed at low levels (Figure 1B).

In the M74 melanoma cell line, the pan-HLA-G primers detect bands corresponding to HLA-G1 and HLA-G5 (1000 bp) (strong signals), a signal for HLA-G2 and G4 (600 bp), but no signal for HLA-G3 (300 bp) (Figure 1A). The primers for the specific isoforms reveal that, in these cells, the G1 and G4 isoforms are more abundant than in the PBMCs, while the level of G5 transcript is comparable to that observed in the PBMCs.

Low levels of HLA-G2 and HLA-G6 (soluble form of HLA-G2) mRNA are detected in these M74 cells, while

specific amplification of the HLA-G3 transcript confirms the absence of HLA-G3 which is observed with the pan-HLA-G primers in these cells (Figures 1A and 1B).

5           No HLA-G hybridization signal is observed in M8 cells (Figures 1A and 1B).

**2/ Analysis of the HLA-G proteins in melanoma cells.**

10           In order to determine whether the HLA-G transcripts which are detected in the melanomas are translated into HLA-G proteins, immunoprecipitation studies were carried out with various anti-HLA class I monoclonal antibodies.

15           The comparison is performed in the presence of a positive control (JEG-3 cell) and a negative control (M8 melanoma cells).

          The results of immunoprecipitation with the W6/32 monoclonal antibody are illustrated in Figure 3.

20           With the JEG-3 cells, the W6/32 antibody immunoprecipitated two proteins of 45 KDa (HLA-C molecule) and of 39 KDa (membrane bound HLA-G1 isoform).

          In the IGR and M8 cells, only one protein of 45 KDa is detected.

25           Similar results are obtained by immunoprecipitation of biotinylated surface proteins (Figure 3).

30           These data show that the HLA-G1 protein is not expressed in the IGR cells, even though the latter express the corresponding mRNA.

          However, the absence of HLA-G1 protein in the IGR cells does not exclude the expression of 3 other HLA-G isoforms (HLA-G2, G3 and G4).

35           These proteins cannot be revealed by the W6/32 monoclonal antibody, because of their inability to associate with  $\beta$ 2m.

          To reveal these proteins, immunoprecipitation of methionine-labelled ( $^{35}\text{S}$ -methionine) proteins is carried out using monoclonal antibodies which recognize

free HLA-G, denatured HLA-G and HLA-A (HCA2 antibodies) and an epitope which is located in the  $\alpha 1$  domain which is present in all the isoforms of the HLA-G protein (anti-HLA-G Ig monoclonal antibody).

5           The monoclonal antibody reveals the presence of the 39-KDa HLA-G1 protein in the JEG-3 and DRAN cells, and its absence in the IGR cells (Figure 4).

          Additional bands, which migrate at 32 to 34 KDa and at 18 KDa, and which correspond to the size of the  
10 HLA-G2 protein and/or of the HLA-G4 or G3 protein, respectively, are detected in the IGR cells both with the anti-HLA-G Ig monoclonal antibody and with the HCA2 antibody (Figure 4).

          The additional bands, which are specific to the  
15 HLA-G protein, are not observed in the M74 and M8 cells, which do not exhibit the corresponding HLA-G transcripts (Figure 4).

**3/ Protection of the IGR line against NK cell-induced cytotoxicity.**

20           The YT2C2-PR cells are used as NK effector cells.

          The IGR cell line, which expresses the HLA-G2 and/or G4 and G3 isoforms, and the DRAN line, which expresses HLA-G1, abolish clone YT2C2-PR-induced lysis  
25 (Figure 5).

          The M74 melanoma cell line, which expresses the conventional MHC class I antigens, but which exhibits a selective deficiency in the transcription and expression of the HLA-G2 and HLA-G3 isoforms, is lysed  
30 by the clone YT2CT-PR.

          Lysis is also observed with the M8 cell line, which expresses the conventional MHC class I antigens, but which transcribes no HLA-G mRNA (Figures 1 and 5).

          In order to show that only the HLA-Gs are  
35 involved in this inhibition of NK cell-induced lysis, several EBV-B cell lines which express no HLA-G, but which share at least one HLA-A, B or C allele with the IGR line, are used as target cells.

All these EBV-B lines are lysed by the clone YT2C2-PR, showing that the HLA-A, B and C antigens are not involved in protecting the IGR and DRAN melanomas against the YT2C2-PR lysis (Figure 5).

5           In order to show that the clone YT2C2-PR-induced lysis, by the IGR cells, is not due to a signal which is transmitted by this cell line, but is indeed linked to an intrinsic resistance of these IGR cells to NK cells, the IGR cells were used as inhibitors in a  
10 cytotoxicity assay in which the target cells (T) are M8 cells and the YT2C2-PR cells are the effector cells (E).

Figure 5B shows that the IGR cells effectively inhibit lysis of the M8 cells by the clone YT2C2-PR; 15 this inhibition is proportional to the number of IGR cells used for the competitive assay.

**EXAMPLE 2: Detection of HLA-G transcripts and proteins in melanoma biopsies.**

A/ MATERIALS AND METHODS

20           **1/ Tumour samples**

Biopsies are performed on tissue samples from patients.

Immediately after removal, the samples are frozen in liquid nitrogen and stored until extraction  
25 of the RNA.

**2/ Immunohistochemistry**

Standard methods are used to carry out the immunohistochemistry on sections which are prepared from the melanoma biopsies, fixed with acetone, rinsed  
30 in PBS and blocked in normal rabbit serum (DAKO) in PBS.

The samples are incubated with the primary antibody for 1 h at room temperature, and are then incubated with a secondary antibody (FITC-conjugated  
35 rabbit anti-mouse Ig) (DAKO).

The sections are counterstained with a nuclear dye (DAPI, Sigma) and prepared in a suitable medium. The fluorescence is analysed using an Io24 MRC confocal microscope (Bio-Rad). The following antibodies are

used: W6/32: anti- $\beta$ 2-microglobulin-associated HLA-G class I heavy chain IgG2a (Sigma) and 87G: anti-HLA-G IgG2b which detects the HLA-G1 isoform.

The other techniques are identical to those in  
5 Example 1.

B/ RESULTS

1/ Analysis of HLA-G transcription in melanoma biopsies ex vivo.

In some melanoma biopsies, all the HLA-G  
10 transcripts are detected at significant levels, whereas only the 1000-bp band is detected in the healthy human skin (Figures 2 and 6). These results were confirmed on other biopsies and show that the significant  
15 transcription levels observed in the melanoma cells are specific for the latter and cannot be observed in healthy tissue.

More precisely, high levels of HLA-G  
transcription are detected specifically in primary  
tumours and in metastases, whereas basal levels of  
20 HLA-G transcripts and an absence of expression of HLA-G protein are observed in healthy skin or in normal lymph nodes (Figure 6A).

The analysis of the healthy skin (HS1), of the  
skin primary tumours (SP1) and of a tumour regression  
25 site (R1) in a skin primary tumour from the same patient enables the detection of a high level of HLA-G transcripts and of protein expression at the primary tumour site, whereas both the healthy skin and the tumour regression site exhibit basal levels of HLA-G  
30 transcripts and a complete absence of the expression of HLA-G1 proteins (Figure 7).

The cultured primary cells (MPP5) which are  
derived from the primary tumour SP1 also exhibit high  
levels of HLA-G transcripts (Figure 7).

35 2/ Analysis of soluble HLA-G transcription in melanoma biopsies ex vivo

Specific amplification of the transcripts  
(mRNA) corresponding to the HLA-G5 soluble isoform in  
the melanoma biopsies shows that high levels of HLA-G5

transcripts are detected in certain melanoma biopsies which have been shown to exhibit high levels of transcripts corresponding to the membrane-bound isoforms of HLA-G (Figure 8).

5           Moreover, in other cases, a dissociation is observed between the HLA-G5 levels and the levels of the other HLA-G transcripts: in melanoma biopsies in which high HLA-G1, G2, G3 and G4 levels have previously been observed, HLA-G5 transcripts are not observed.

10           The skin primary tumour SP1 and the corresponding cultured cells MPP5, as well as the lymph node metastases LNM2, exhibit high levels of HLA-G transcripts corresponding to membrane-bound HLA-G isoforms (Figure 8) whereas HLA-G5 transcripts are not  
15 detected in the same sample.

**3/ Analysis of the membrane-bound and soluble proteins in melanoma biopsies**

High levels of HLA-G transcripts are correlated with the specific detection of the expression of HLA-G  
20 protein by an anti-HLA-G monoclonal antibody (antibody 87G) in melanoma biopsies. Specifically, the immunohistochemical analysis of the HLA-G expression in a metastatic lymph node (LNM2) biopsy makes it possible to observe positive staining of LNM2 both with the  
25 antibody 87G and with the antibody W6/32, whereas the negative control, which consists of healthy skin from the same patient, is not stained with the anti-HLA-G antibody.

In order to refine this study, an antibody  
30 which specifically detects the soluble HLA-G protein, the antibody 16G1 (Lee et al., Immunity, 1995, 3, 591-600), makes it possible to demonstrate the expression of the soluble HLA-G protein in the lymph node biopsy of a patient exhibiting high levels of HLA-G5  
35 transcripts (Figure 8).

The immunohistochemical analysis enables the staining of this biopsy, while no detectable expression is observed, using the same antibody, in a melanoma

Specifically, the immunohistochemical analysis of the expression of soluble HLA-G in the LNM2 biopsy shows that acetone-fixed LNM2 biopsy sections are positively stained with the anti-melanoma antibody HMB45 (DAKO, Glostrup,; Skelton et al., Am. J. Dermatopathol., 1991, 13, 543-550) and the anti-soluble HLA-G antibody 16G1, whereas the negative control is

10 not stained.

15 encompasses all the variants thereof which may occur to  
persons skilled in the art, without departing from the  
context or the scope of the present invention.

CLAIMS

- 1) Method for establishing the HLA-G transcription profile of a solid tumour with a view to selecting a treatment which is suited to said tumour and/or with a view to monitoring the evolution of said tumour, characterized in that it comprises:
- (i) - the removal of a tumour sample;
  - (ii) the extraction of the mRNA;
  - 10 (iii) the reverse transcription (RT) of said RNA;
  - (iv) the successive or simultaneous amplifications of the cDNAs obtained in (iii), in the presence of primers specific for each HLA-G isoform,
  - 15 and the analysis of the amplification products obtained by electrophoresis and/or specific hybridization and
  - (v) the establishment of the HLA-G transcription profile of said sample.
- 2) Method for establishing the HLA-G expression profile of a solid tumour with a view to selecting a treatment which is suited to said tumour and/or with a view to monitoring the evolution of said tumour, characterized in that it comprises:
- (i) the removal of a tumour sample,
  - 25 (ii) the preparation of a histological section from said sample,
  - (iii) the labelling of the cells of the sample obtained in (ii) with antibodies specific for HLA-G membrane-bound and soluble isoforms, and
  - 30 (iv) the establishment of the HLA-G expression profile of said sample by detecting the labelled cells.
- 3) Method for establishing the HLA-G expression profile of a solid tumour with a view to selecting a treatment which is suited to said tumour and/or with a view to monitoring the evolution of said tumour, characterized in that it comprises:
- (i) the removal of a tumour sample,



(ii) optionally, the labelling of the cells of said sample,

(iii) the lysis of the cells,

(iv) the bringing of the lysed cells into  
5 contact with various antibodies directed against the class I HLA antigens so as to possibly form HLA-G isoform/antibody complexes, and

(v) the establishment of the HLA-G expression profile of said sample by detecting the  
10 complexes formed in step (iv).

4) Method for selecting factors for regulating the transcription and/or the expression of HLA-Gs by tumour cells, this method being characterized in that it comprises:

15 (i) the removal of a tumour sample,

(ii) the isolation of the tumour cells from said sample,

(iii) the primary culture of the tumour cells obtained in (ii),

20 (iv) the addition of the substance to be tested,

(v) the visualization of the effect obtained by establishing the HLA-G transcription and/or expression profile of said tumour cells after treatment  
25 with said substance to be tested, and

(vi) the testing in vitro of the effect of the treatment on the antitumour response.

5) Antitumour vaccine which can be used for solid tumours expressing at least one HLA-G isoform,  
30 characterized in that it is selected from the group consisting of autologous tumour cells and a soluble HLA-G5 antigen or a fragment thereof.

6) Vaccine according to Claim 5, characterized in that when said vaccine consists of tumour cells from  
35 the individual to be treated which express at least one HLA-G isoform, said cells are modified so as to induce the production of anti-HLA-G antibodies.

7) Vaccine according to Claim 5, characterized in that said soluble HLA-G antigen, or a fragment thereof,

is coupled to a suitable protein and optionally combined with an adjuvant such as aluminium hydroxide or calcium phosphate.

8) Antitumour composition which can be used for  
5 solid tumours expressing at least one HLA-G isoform, characterized in that it consists essentially of anti-HLA-G antibodies.

9) Antitumour composition which can be used for  
10 solid tumours expressing at least one HLA-G isoform, characterized in that it consists essentially of at least one factor for regulating the transcription and/or the expression of HLA-Gs.

10) Composition according to Claim 9, characterized  
15 in that said regulation factor is selected from the group consisting of the regulation factors obtained using the method according to Claim 4, factors which are antagonists of HLA-G activation agents, antisense nucleic acids and hormonal inhibitors of the transcription and/or of the expression of said HLA-Gs.

20 11) Products containing anti-HLA-G antibodies and factors for regulating the expression of HLA-Gs as combination products for simultaneous or separate use, or use which is spread out over time, in the treatment of solid tumours expressing at least one HLA-G isoform.

25 12) Method for studying the transcription and/or the expression of the HLA-Gs, characterized in that it consists of a cell culture which is established from a tumour tissue biopsy.

30 13) Method for monitoring the evolution of a tumour expressing HLA-G, characterized in that it comprises assaying the soluble form of HLA-G in the sera of patients, as a prognostic factor for tumour dissemination or for the capacity of a tumour to form metastases.

**ABSTRACT**

The invention concerns a method for selecting tumours expressing HLA-G, sensitive to an anticancer treatment, which inhibits or prevents the HLA-G activity of said tumours and the uses thereof. Said method enable to establish either the HLA-G, transcription profile of a solid tumour or the HLA-G expression profile of a solid tumour. The method for establishing the HLA-G transcription profile consists in: (i) drawing a tumoral sample; (ii) extracting the mRNA; (iii) reverse transcription (RT) of said RNA: (iv) successive or simultaneous amplification of the cDNA's obtained in (iii) in the presence of primers specific to each HLA-G isoform and analysing the resulting amplification products, by electrophoresis and/or specific hybridisation and (v) establishing said sample HLA-G transcription profile. The method for establishing the HLA-G expression profile consists in: (i) drawing a tumoral sample; (ii) optionally marking said sample cells; (iii) carrying out a lysis of the cells; (iv) contacting said cells which have been subjected to lysis with different antibodies directed against the class I HLA-G antigens, to form, optionally HLA-G isoform/antibodies complexes; and (v) establishing said sample HLA-G expression profile by detecting the complexes formed in step (iv).

1/12




FIGURE 1A




FIGURE 1B

2/12




FIGURE 1C




FIGURE 2

3/12




FIGURE 3

4/12




FIGURE 4

5/12




FIGURE 5B

FIGURE 5A



6/12





FIGURE 5C

7/12



**FIGURE 5D**

8/12




FIGURE 5E




FIGURE 6

10/12





FIGURE 7

11/12



11/12

12/12




FIGURE 8B

**Declaration and Power of Attorney for Patent Application**  
**Déclaration et Pouvoirs pour Demande de Brevet**  
**French Language Declaration**

En tant l'inventeur nommé ci-après, je déclare par le présent acte que :

Mon domicile, mon adresse postale et ma nationalité sont ceux figurant ci-dessous à côté de mon nom.

Je crois être le premier inventeur original et unique (si un seul nom est mentionné ci-dessous), ou l'un des premiers co-inventeurs originaux (si plusieurs noms sont mentionnés ci-dessous) de l'objet revendiqué, pour lequel une demande de brevet a été déposée concernant l'invention intitulée

et dont la description est fournie ci-joint à moins

- ☐ ci-joint  
☐ a été déposée le

sous le numéro de demande des Etats-Unis ou le numéro de demande international PCT

et modifiée le

(le cas échéant).

Je déclare par le présent acte avoir passé en revue et compris le contenu de la description ci-dessus, revendications comprises, telles que modifiées par toute modification dont il aura été fait références ci-dessus.

Je reconnais devoir divulguer toute information pertinente à la brevetabilité, comme défini dans le Titre 37, § 1.56 du Code fédéral des réglementations.

As a below named inventor, I hereby declare that :

My residence, post office address and citizenship are as stated next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed an for which a patent is sought on the invention entitled

**Method for selecting tumours expressing HLA-G, sensitive to anticancer treatment and uses**

the specification of which :

- ☐ is attached hetero.  
☒ was filed on

as United States Application Number or PCT International Application Number.  
**PCT/FR99/00386** filed on February 19, 1999

and was amended on

(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.





## French Language Declaration

Je revendique par le présent acte avoir la priorité étrangère, en vertu du Titre 35, § 119(a)-(d) ou § 365(b) du Code des Etats-Unis, sur toute demande étrangère de brevet ou certificat d'inventeur ou, en vertu du Titre 35, § 365(a) du même Code, sur toute demande internationale PCT désignant au moins un pays autre que les Etats-Unis et figurant ci-dessous et, en cochant la case, j'ai aussi indiqué ci-dessous toute demande étrangère de brevet, tout certificat d'inventeur ou toute demande internationale PCT ayant date de dépôt précédant celle de la demande à propos de laquelle une priorité est revendiquée.

Prior Foreign application(s)

Demande(s) de brevet antérieure(s) dans un autre pays.

**98 02071                      FRANCE**

(Number)                      (Country)  
(Numéro)                      (Pays)

**98 09470                      FRANCE**

(Number)                      (Country)  
(Numéro)                      (Pays)

Je revendique par le présent acte tout bénéfice, en vertu du Titre 35, § 119(e) du Code des Etats-Unis, de toute demande de brevet provisoire effectuée aux Etats-Unis et figurant ci-dessous.

(Application No.)                      (Filing Date)  
(N° de demande)                      (Date de dépôt)

Je revendique par le présent acte tout bénéfice, en vertu du Titre 35, § 120 du Code des Etats-Unis, de toute demande de brevet effectuée aux Etats-Unis, ou en vertu du Titre 35, § 365(c) du même Code, de toute demande internationale PCT désignant les Etats-Unis et figurant ci-dessous et, dans la mesure où l'objet de chacune des revendications de cette demande de brevet n'est pas divulgué dans la demande antérieure américaine ou internationale PCT, en vertu des dispositions du premier paragraphe du Titre 35, § 112 du code des Etats-Unis, je reconnais devoir divulguer toute information pertinente à la brevetabilité, comme défini dans le Titre 37, § 1.56 du Code fédéral des réglementations, dont j'ai pu disposer entre la date de dépôt de la demande antérieure et la date de dépôt de la demande nationale ou internationale PCT de la présente demande :

(Application No.)                      (Filing Date)  
(N° de demande)                      (Date de dépôt)

(Application No.)                      (Filing Date)  
(N° de demande)                      (Date de dépôt)

Je déclare que par le présent acte que toute déclaration ci-incluse est, à ma connaissance, véridique et que toute déclaration formulée à partir de renseignements ou de suppositions est tenue pour véridique ; et de plus, que toutes ces déclarations ont été formulées en sachant que toute fausse déclaration volontaire ou son équivalent est passible d'une amende ou d'une incarcération, ou des deux, en vertu de la section 1001 du Titre 18 du Code des Etats-Unis, et que de telles déclarations volontairement fausses risquent de compromettre la validité de la demande de brevet ou du brevet délivré à partir de celle-ci.

I hereby claim foreign priority under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below, and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Priority claimed  
Droit de priorité  
revendiqué

(Day/Month/Year Filed)                      ☒                      ☐  
(Jour/Mois/Anné de dépôt)                      Oui                      Non

20.02.1998

(Day/Month/Year Filed)                      ☒                      ☐  
(Jour/Mois/Anné de dépôt)                      Oui                      Non

24.07.1998

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

(Application No.)                      (Filing Date)  
(N° de demande)                      (Date de dépôt)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

(Status) (patented, pending, abandoned)  
(Statut) (breveté, en cours d'examen, abandonné)

(Status) (patented, pending, abandoned)  
(Statut) (breveté, en cours d'examen, abandonné)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true ; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



## French Language Declaration

POUVOIRS : En tant que l'inventeur cité, je désigne par la présente l'(les) avocat(s) et/ou agent(s) suivant(s) pour qu'ils poursuive(nt) la procédure de cette demande de brevet et traite(nt) toute affaire s'y rapportant avec l'Office des brevets et des marques : (mentionner le nom et le numéro d'enregistrement).

POWER OF ATTORNEY : As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to persecute this application and transact all business in the Patent and Trademark Office connected therewith : (list name and registration number)

29

Norman F. Oblon, Reg. No. 24,618 ; Marvin J. Spivak, Reg. No. 24,913 ; C. Irvin McClelland, Reg. No. 21,124 ; Gregory J. Maier, Reg. No. 25,599 ; Arthur I. Neustadt, Reg. No. 24,854 ; Richard D. Kelly, Reg. No. 27,757 ; James D. Hamilton, Reg. No. 28,421 ; Eckhard H. Kuesters, Reg. No. 28,870 ; Robert T. Pous, Reg. No. 29,099 ; Charles L. Gholz, Reg. No. 26,395 ; William E. Beaumont, Reg. No. 30,996 ; Jean-Paul Lavalleye, Reg. No. 31,451 ; Stephen G. Baxter, Reg. No. 34,884 ; Richard L. Treanor, Reg. No. 36,379 ; Stephen P. Weihrouch, Reg. No. 32,829 ; John T. Goolkasian, Reg. No. 26,142 ; Richard L. Cinn, Reg. No. 34,305 ; Stephen E. Lipman, Reg. No. 30,011 ; Carl E. Shlier, Reg. No. 34,426 ; James J. Kubaski, Reg. No. 34,648 ; Richard A. Neifeld, Reg. No. 35,299 ; J. Dereck Mason, Reg. No. 35,270 ; Surinder Sachar, Reg. No. 34,423 ; Christina M. Gadiano, Reg. No. 37,628 ; Jeffrey B. McIntyre, Reg. No. 36,867 ; William T. Enos, Reg. No. 33,128 ; Michael E. McCabe, Jr., Reg. No. 37,182 ; Bradley D. Lytle, Reg. No. 40,073 ; and Michael R. Asey, Reg. No. 40,294, with full powers of substitution and revocation.

Addresser toute correspondance à :

Send Correspondence to :

**OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.**  
FOURTH FLOOR  
1755 JEFFERSON DAVIS HIGHWAY  
ARLINGTON, VIRGINIA 22202 U.S.A.

Adresser tout appel téléphonique à :  
(nom et numéro de téléphone)

Direct Telephone calls to : (name and telephone number)




(703) 413-3000

1-00	Nom complete de l'unique ou premier inventeur <b>Edgardo, Delfino CAROSELLA</b>	Full name of sole or first inventor
	Signature de l'inventeur <i>[Signature]</i> Date <b>20.09.00</b>	Inventor's signature Date
	Domicile <b>F 75016 PARIS (France)</b> <i>FRX</i>	Residence
	Nationalité <b>Française</b>	Citizenship
	Adresse Postale <b>23, rue George Sand F 75016 PARIS (France)</b>	Post Office Address
2-00	Nom complete du second co-inventeur, le cas echeant <b>Jean DAUSSET</b>	Full name of second joint inventor, if any
	Signature de l'inventeur <i>[Signature]</i> Date <b>26.04.00</b>	Second inventor's signature Date
	Domicile <b>F 75007 PARIS (France)</b> <i>FRX</i>	Residence
	Nationalité <b>Française</b>	Citizenship
	Adresse Postale <b>9, rue Villersexel F 75007 PARIS (France)</b>	Post Office Address
	<b>44, rue des Ecoles F-75005 Paris</b>	

(Fournir les mêmes renseignements et la signature de tout co-inventeur supplémentaire.)

(Supply similar information and signature for third and subsequent joint inventors.)

## French Language Declaration

300 Nom complete du troisième co-inventeur, le cas échéant Philippe MOREAU		Full name of third joint inventor, if any	
Signature de l'inventeur 	Date 20.09.2000	Third inventor's signature Date	
Domicile F-91170 VIRY-CHATILLON (France) FRX		Residence	
Nationalité Française		Citizenship	
Adresse Postale 8, rue Bougainville F-91170 VIRY-CHATILLON (France)		Post Office Address	
400 Nom complete du quatrième co-inventeur, le cas échéant Pascale PAUL		Full name of fourth joint inventor, if any	
Signature de l'inventeur 	Date 22.09.2000	Fourth inventor's signature Date	
Domicile F-75010 PARIS (France) FRX		Residence	
Nationalité Française		Citizenship	
Adresse Postale 29, rue de la Grange aux Belles F-75010 PARIS (France)		Post Office Address	
500 Nom complete du cinquième co-inventeur, le cas échéant Nathalie ROUAS-FREISS		Full name of fifth joint inventor, if any	
Signature de l'inventeur 	Date 20.9.2000	Fifth inventor's signature Date	
Domicile F-75013 PARIS (France) FRX		Residence	
Nationalité Française		Citizenship	
Adresse Postale 44, boulevard Arago F-75013 PARIS (France)		Post Office Address	
Nom complete du sixième co-inventeur, le cas échéant		Full name of sixth joint inventor, if any	
Signature de l'inventeur	Date	Sixth inventor's signature Date	
Domicile		Residence	
Nationalité		Citizenship	
Adresse Postale		Post Office Address	

(Fournir les mêmes renseignements et la signature de tout co-inventeur supplémentaire.)

(Supply similar information and signature for third and subsequent joint inventors.)